Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Authors
Keywords
-
Journal
Metabolites
Volume 11, Issue 1, Pages 22
Publisher
MDPI AG
Online
2020-12-31
DOI
10.3390/metabo11010022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
- (2020) Lars Johansson et al. DIABETES OBESITY & METABOLISM
- Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
- (2020) Rod S. Taylor et al. GASTROENTEROLOGY
- Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions
- (2020) Kenneth Cusi LIVER INTERNATIONAL
- Complications, morbidity and mortality of nonalcoholic fatty liver disease
- (2020) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
- (2020) Eugene Han et al. Journal of Clinical Medicine
- SGLT2 inhibitors in liver patients
- (2020) John Chen Hsiang et al. Clinical Gastroenterology and Hepatology
- Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
- (2020) Tomoe Kinoshita et al. Journal of Diabetes Investigation
- A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
- (2020) John A. Dougherty et al. ANNALS OF PHARMACOTHERAPY
- Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
- (2020) Silvina Gallo et al. Diabetes Therapy
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
- (2020) Jonathan G. Stine et al. Clinical Gastroenterology and Hepatology
- Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
- (2020) Jeffrey Budd et al. Current Diabetes Reports
- Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
- (2020) Alessandro Mantovani et al. GUT
- Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
- (2020) André J. Scheen Nature Reviews Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sex Differences in NAFLD : State of the Art and Identification of Research Gaps
- (2019) Amedeo Lonardo et al. HEPATOLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
- (2019) A.J. Scheen DIABETES & METABOLISM
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats
- (2019) Myat Theingi Swe et al. CLINICAL SCIENCE
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
- (2018) Cyrielle Caussy et al. HEPATOLOGY
- Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
- (2018) Boyu Li et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
- (2018) Alessandro Mantovani et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
- (2018) Frédéric Brioude et al. Nature Reviews Endocrinology
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- (2017) Zobair Younossi et al. Nature Reviews Gastroenterology & Hepatology
- Effects of canagliflozin on weight loss in high-fat diet-induced obese mice
- (2017) Wenjun Ji et al. PLoS One
- EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
- (2016) Guntram Schernthaner et al. CLINICAL THERAPEUTICS
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
- (2015) Amedeo Lonardo et al. DIGESTIVE AND LIVER DISEASE
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Luseogliflozin: First Global Approval
- (2014) Anthony Markham et al. DRUGS
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now